Candidate Compounds Covid19

Aus coViki
Wechseln zu: Navigation, Suche

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

current items will be put into the subsections.




-rest-

009


32459647 2020. Intra-Rater and Inter-Rater Reliability of Tongue Coating Diagnosis in Traditional Chinese Medicine Using Smartphones: Quasi-Delphi Study.

















32464494 2020. Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19.



32464492 2020. Can moderate intensity aerobic exercise be an effective and valuable therapy in preventing and controlling the pandemic of COVID-19?




32516733 2020. B-cell engineering: A promising approach towards vaccine development for COVID-19.



32505075 2020. Fighting against frailty and sarcopenia - As well as COVID-19?


32505069 2020. Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic.


32395220 2020. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.



32473390 2020. A review of South Indian medicinal plant has the ability to combat against deadly viruses along with COVID-19?



32442649 2020. Plant Solutions for the COVID-19 Pandemic and Beyond: Historical Reflections and Future Perspectives.



32445439 2020. Surgery Scheduling in a Crisis.







32521760 2020. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review.
32532069 2020. Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection?


32528623 2020. COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment?


32431755 2020. The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.
32451736 2020. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19.


32445955 2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"


32430287 2020. Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.



32405226 2020. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.




32470470 2020. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.
32442437 2020. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
32437972 2020. COVID-19: Beyond the virus. The use of Photodynamic Therapy for the Treatment of Infections in the Respiratory Tract.


32493609 2020. SGLT-2 inhibitors for COVID-19 - A miracle waiting to happen or just another beat around the bush?


32415971 2020. Use of statins in patients with COVID-19.
32415962 2020. Reply: Use of statins in patients with COVID-19.
32522574 2020. Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?



32426002 2020. Opciones Terapeuticas En El Manejo De Covid-19 Grave: Una Perspectiva De Reumatologia.



32414660 2020. Exercising in times of COVID-19: what do experts recommend doing within four walls?





32412544 2020. In silico fight against novel coronavirus by finding chromone derivatives as inhibitor of coronavirus main proteases enzyme.



32436460 2020. TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.


32406985 2020. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.


32376108 2020. Archetype analysis of older adult immunization decision-making and implementation in 34 countries.




32532094 2020. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.


32426090 2020. COVID-19, asthma, and biologic therapies: What we need to know.


32514854 2020. Biologikatherapie nach COVID-19-Infektion : Keine Reaktivierung einer COVID-19-Infektion bei positivem Antikorperstatus SARS-CoV-2 unter Biologikatherapie.






32574894 2020. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic.
32583087 2020. IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.



32575554 2020. Targeting the Heme-Heme Oxygenase System to Prevent Severe Complications Following COVID-19 Infections.


32557214 2020. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.



32541865 2020. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.


32585295 2020. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.



32558354 2020. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load.
32552848 2020. Compassionate use of others' immunity - understanding gut microbiome in Covid-19.



32578027 2020. A Rapid Advice Guideline for the Prevention of Novel Coronavirus Through Nutritional Intervention.
32562159 2020. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.



32537890 2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19.
32592841 2020. A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19.
32581194 2020. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?



32569833 2020. Exportin 1 inhibition as antiviral therapy.



32592145 2020. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.
32574958 2020. Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.



32562594 2020. Pregnant Women in Trials of COVID-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.
32561291 2020. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?
32554535 2020. Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors (nAChR) and beyond.
32578073 2020. Elderly at time of COronaVIrus disease 2019 (COVID-19): possible role of immunosenescence and malnutrition.
32577840 2020. Introduction: microbes, networks, knowledge-disease ecology and emerging infectious diseases in time of COVID-19.
32546029 2020. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.


32588335 2020. COVID-19, equipoise and observational studies: a reminder of forgotten issues.
32557206 2020. Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.




32579907 2020. Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19.


32592113 2020. Potential role of incretins in diabetes and COVID-19 infection: a hypothesis worth exploring.




32552021 2020. From "Infodemics" to Health Promotion: A Novel Framework for the Role of Social Media in Public Health.
32579022 2020. Lung Mechanics in COVID-19 Resemble RDS not ARDS: Could Surfactant be a Treatment?
32579020 2020. Treatment of COVID-19 by Inhaled NO to Reduce Shunt?
32551560 2020. Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.



32561608 2020. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.
32574109 2020. Structural Basis of the SARS-CoV-2/SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics.




32562762 2020. SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?



32559771 2020. The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin.


32567239 2020. Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.



32552044 2020. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges.
32576053 2020. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients.
32553760 2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.
32553757 2020. Aminosalicylates and COVID-19: Facts or Coincidences?
32554621 2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.



32557541 2020. A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.
32561274 2020. In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.



32562701 2020. Apelin-potential therapy for COVID-19?




32555296 2020. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).



32590324 2020. Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis.
32575019 2020. Pirfenidone: A novel hypothetical treatment for COVID-19.
32558640 2020. Cibler la protease majeure du SARS-CoV-2 pour fabriquer un medicament efficace contre ce coronavirus.


32574789 2020. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).
32570850 2020. Microbiota Modulating Nutritional Approaches to Countering the Effects of Viral Respiratory Infections Including SARS-CoV-2 through Promoting Metabolic and Immune Fitness with Probiotics and Plant Bioactives.
32546125 2020. Erythropoietin as candidate for supportive treatment of severe COVID-19.
32560203 2020. Quinoxaline Derivatives as Antiviral Agents: A Systematic Review.


32557405 2020. Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences.
32576980 2020. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.



32587103 2020. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
32590117 2020. Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19.


32564413 2020. Is 0.5% Hydrogen Peroxide Effective against SARS-CoV-2?
32587806 2020. A potential role for Galectin-3 inhibitors in the treatment of COVID-19.



32565309 2020. Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.
32592716 2020. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?
32562826 2020. Therapeutic potential of resveratrol against emerging respiratory viral infections.
32542785 2020. Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID-19.
32592911 2020. Does photodynamic therapy have potential in the treatment of COVID 19 patients?
32585401 2020. Optical theranostics and treatment dosimetry for COVID-19 lung complications: towards increasing the survival rate of vulnerable populations.
32585400 2020. Ultraviolet-based biophotonic technologies for control and prevention of COVID-19, SARS and related disorders.




32552811 2020. E-cigarette-induced pulmonary inflammation and dysregulated repair are mediated by nAChR alpha7 receptor: role of nAChR alpha7 in SARS-CoV-2 Covid-19 ACE2 receptor regulation.


32557955 2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.
32571730 2020. Anakinra, una alternativa potencial en el tratamiento de la infeccion respiratoria grave por SARS-CoV-2 refractaria a tocilizumab.

32579014 2020. Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19.
32579012 2020. COVID-19. Immunothrombosis and the gastrointestinal tract.



32593196 2020. The Another Side of COVID-19 in Alzheimer's Disease Patients: Drug-Drug Interactions.



32586154 2020. Montelukast's ability to fight COVID-19 infection.
32583729 2020. Immunoinformatics study to search epitopes of spike glycoprotein from SARS-CoV-2 as potential vaccine.
32579065 2020. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2.


32579061 2020. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL(pro).


32573355 2020. Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study.


32571168 2020. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.


32568618 2020. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors.
32568613 2020. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study.
32568013 2020. Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2.
32568012 2020. Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach.
32567995 2020. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.
32567989 2020. In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2.
32567979 2020. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.
32567501 2020. Constituents of buriti oil (Mauritia flexuosa L.) like inhibitors of the SARS-Coronavirus main peptidase: an investigation by docking and molecular dynamics.



32559419 2020. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.


32574572 2020. Letter to the editor: Immunomodulation by phsphodiesterase-4 inhibitor in COVID-19 patients.
32579258 2020. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.
32578354 2020. Obesity and COVID-19: The mTOR pathway as a possible culprit.


32588453 2020. Covid-19 and Thymoquinone: Connecting the Dots.

32552307 2020. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors.


32569363 2020. Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab - A Case- Controlled Study.


32568376 2020. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.
32556278 2020. Real-life experience of tocilizumab use in COVID-19 patients.
32543892 2020. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.



32573990 2020. Heart Transplant Recipient Patient with COVID-19 Treated with Tocilizumab.
32584762 2020. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].




32547694 2020. Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps.
32547693 2020. A Role for Metal-Based Drugs in Fighting COVID-19 Infection? The Case of Auranofin.



32593520 2020. Tocilizumab en nino con leucemia linfoblastica aguda y sindrome de liberacion de citoquinas asociado a COVID-19.
32566569 2020. Appealing for efficient, well organized clinical trials on COVID-19.




32545171 2020. Antimicrobial Photodynamic Therapy in the Control of COVID-19.
32545518 2020. Nrf2 Activator PB125((R)) as a Potential Therapeutic Agent against COVID-19.


32536457 2020. Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?
32546446 2020. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?


32594322 2020. Antiviral activity of berberine.


32593613 2020. Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction.




32599963 2020. Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis.
32536632 2020. Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19.
32459144 2020. Discovery of alliin as a putative inhibitor of the main protease of SARS-CoV-2 by molecular docking.
32532425 2020. Inclusion of pregnant women in clinical trials of COVID-19 therapies: what have we learned?
32557557 2020. Harnessing resolving-based therapeutics to treat pulmonary viral infections: What can the future offer to COVID-19?


32571773 2020. Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018.





32603679 2020. Calcineurin inhibitors revisited: A new paradigm for COVID-19?



32383125 2020. Prophylaxie post-exposition ou traitement preventif pour le syndrome respiratoire aigu severe du coronavirus 2 (SARS-CoV-2) : protocole d'etude pour une etude randomisee controlee pragmatique.


32385712 2020. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
32389579 2020. Irradiation pulmonaire a faible dose pour l'orage de cytokines du COVID-19 : pourquoi pas ?
32411313 2020. FAVORABLE ANAKINRA RESPONSES IN SEVERE COVID-19 PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS.




32409956 2020. Possible application of H2S-producing compounds in therapy of coronavirus (COVID-19) infection and pneumonia.


32599278 2020. Imatinib for COVID-19: A case report.
32607779 2020. Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?
32594204 2020. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?



32598985 2020. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.



32606823 2020. Potential Role of Nrf2 Activators with Dual Antiviral and Anti-Inflammatory Properties in the Management of Viral Pneumonia.


32610153 2020. COVID-19 trials in Italy: A call for simplicity, top standards and global pooling.




32593183 2020. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.

32584421 2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.


32584416 2020. Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome.


32536693 2020. Antiviral Therapy during the Coronavirus Disease (COVID-19) Pandemic: Is It Appropriate to Treat Patients in the Absence of Significant Evidence?


32553536 2020. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients: Survival and Clinical Outcomes.



32573419 2020. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
32597466 2020. Use of Baricitinib in Patients with Moderate and Severe COVID-19.


32594120 2020. Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors.
32575124 2020. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia.



32536564 2020. IL-15 immunotherapy is a viable strategy for COVID-19.
32540737 2020. Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): Boon or bane?


32603531 2020. Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.



32518817 2020. Synthesis, Spectroscopic Characterizations of Novel Norcantharimides, Their ADME Properties and Docking Studies Against COVID-19 M(pr) degrees .
32572383 2020. Evaluation of the Inhibitory Activities of COVID-19 of Melaleuca cajuputi Oil Using Docking Simulation.


32548601 2020. Ventilation in the Dental Clinic: An Effective Measure to Control Droplets and Aerosols during the Coronavirus Pandemic and Beyond.
32548600 2020. Preventive and Control Measures for the Coronavirus Pandemic in Clinical Dentistry.
32242749 2020. Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection?


32533455 2020. Azithromycin for COVID-19: More Than Just an Antimicrobial?



32544611 2020. Development of child immunity in the context of COVID-19 pandemic.


32417594 2020. Supplements for COVID-19: A modifiable environmental risk.
32405269 2020. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
32409832 2020. SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir.


32407539 2020. Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?


32311763 2020. Off-Label Therapies for COVID-19-Are We All In This Together?



32388748 2020. Reply to Rheumatologists' perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?


32575032 2020. Participation of more community hospitals in randomized trials of treatments for COVID-19 is needed.


32392494 2020. Sample sizes in COVID-19-related research.
32485652 2020. Interaction of the prototypical alpha-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complex.



32384906 2020. Use of triiodothyronine to treat critically ill COVID-19 patients: a new clinical trial.



32513242 2020. Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease.
32513225 2020. Neutrophil Elastase Inhibitors: A potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications?
32487260 2020. Precision medicine for COVID-19: a call for better clinical trials.
32487139 2020. Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure?




32494546 2020. Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials.


32550078 2020. Heated Air Delivery by Micro-Sauna: An Experimental Treatment Prototype Concept for Coronavirus Disease 2019.


32563554 2020. Should we unstress SARS-CoV-2 infected cells?



32593491 2020. Molecular pharmacology of ciclesonide against SARS-CoV-2.



32605278 2020. Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19.



32605149 2020. Bioactive Indolyl Diketopiperazines from the Marine Derived Endophytic Aspergillus versicolor DY180635.
32593831 2020. Plausible role of combination of Chlorpromazine hydrochloride and Teicoplanin against COVID-19.


32593740 2020. Irisin modulates genes associated with severe coronavirus disease (COVID-19) outcome in human subcutaneous adipocytes.
32602074 2020. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.



32597315 2020. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
32608329 2020. In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme.
32520770 2020. Overview of Coronavirus Disease 2019 (COVID-19): Treatment Updates and Advances.
32530870 2020. Rapid Review: Nonsteroidal Anti-inflammatory Agents and Aminosalicylates in COVID-19 Infections.
32570043 2020. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.




32579254 2020. SARS-CoV-2 and SARS-CoV: Virtual Screening of Potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12).
32568411 2020. Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm.
32574379 2020. A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer"on https://doi.org/10.1111/jnc.15021.

32597503 2020. Melatonin Restores Neutrophil Functions and Prevents Apoptosis amid Dysfunctional Glutathione Redox System.


32543164 2020. The comparison of the effectiveness of lincocin(R) and azitro(R) in the treatment of covid-19-associated pneumonia: A prospective study.
32608097 2020. Comparison of In Vitro Inactivation of SARS CoV-2 with Hydrogen Peroxide and Povidone-Iodine Oral Antiseptic Rinses.



32541129 2020. Intermittent high dosage oxygen treats COVID-19 infection: the Chinese studies.
32541128 2020. Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure.



32447665 2020. Mit IL-6-Inhibitor gegen COVID-19 : Corona-Pandemie.
32342366 2020. Autophagie - ein Ansatzpunkt fur ein Medikament gegen COVID-19? : Kampf gegen das Coronavirus.



32524646 2020. Lithium as a candidate treatment for COVID-19: Promises and pitfalls.


32425222 2020. Repurposing chlorpromazine to treat COVID-19: The reCoVery study.



32544799 2020. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.



32563813 2020. Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase.
32525005 2020. Effective block by pirfenidone, an antifibrotic pyridone compound (5-methyl-1-phenylpyridin-2[H-1]-one), on hyperpolarization-activated cation current: An additional but distinctive target.



32399192 2020. Recent advances in influenza vaccines.


32596244 2020. The Inhibitory Effect of Curcumin on Virus-Induced Cytokine Storm and Its Potential Use in the Associated Severe Pneumonia.
32595653 2020. Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm.


32574274 2020. Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing?
32574273 2020. Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?





32582742 2020. The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection.


32574339 2020. Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia.
32574332 2020. Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir.
32574331 2020. May Polyphenols Have a Role Against Coronavirus Infection? An Overview of in vitro Evidence.
32574327 2020. Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19.
32574320 2020. Doxycycline: From Ocular Rosacea to COVID-19 Anosmia. New Insight Into the Coronavirus Outbreak.


32582138 2020. Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection.
32582137 2020. Biosurfactants: A Covid-19 Perspective.
32582134 2020. Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2 Infections.


32581810 2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.
32581809 2020. Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19.
32574238 2020. An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?




32574290 2020. Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic.


32547908 2020. Ultraviolet irradiation doses for coronavirus inactivation - review and analysis of coronavirus photoinactivation studies.
32566483 2020. Doxycycline as a potential partner of COVID-19 therapies.



32540428 2020. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein.
32537482 2020. Screening and druggability analysis of some plant metabolites against SARS-CoV-2: An integrative computational approach.



32534505 2020. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.
32558435 2020. Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond.
32565398 2020. Effects of Micronutrients or Conditional Amino Acids on COVID-19-Related Outcomes: An Evidence Analysis Center Scoping Review.


32552595 2020. Natural compounds from Clerodendrum spp. as possible therapeutic candidates against SARS-CoV-2: An in silico investigation.
32552534 2020. Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation.
32552462 2020. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study.
32552361 2020. Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro).
32544024 2020. An in silico approach for identification of novel inhibitors as potential therapeutics targeting COVID-19 main protease.
32543978 2020. Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials.
32538276 2020. Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies.


32600125 2020. Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection.



32605306 2020. Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2.



32597513 2020. New intrigant possibility for prevention of coronavirus pneumonitis: natural purified polyphenols.
32541085 2020. Citokinellenes terapia az uj tipusu koronavirus okozta megbetegedes (COVID-19) kezeleseben - tocilizumab elsokent valo alkalmazasa egy hazai infektologiai osztalyon.


32579049 2020. Photobiomodulation: Shining Light on COVID-19.
32579493 2020. Response to: Can Transdermal Photobiomodulation Help Us at the Time of COVID-19?
32579491 2020. Author's Response to Ferreira: Can Transdermal Photobiomodulation Help Us at the Time of COVID-19? An Update.




32604223 2020. Therapeutic Potential of B-1a Cells in COVID-19.
32553502 2020. Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic.


32574447 2020. HBO2 for COVID-19: Clinical trials at clinicaltrials.gov.
32574446 2020. UHMS Position Statement: Hyperbaric Oxygen (HBO2) for COVID-19 Patients.
32574433 2020. Hyperbaric oxygen therapy may be effective to improve hypoxemia in patients with severe COVID-2019 pneumonia: two case reports.
32574432 2020. Hyperbaric oxygen as a treatment for COVID-19 infection?
32567972 2020. Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway.



32530282 2020. Computational Determination of Potential Inhibitors of SARS-CoV-2 Main Protease.
32539372 2020. Fragment Molecular Orbital Based Interaction Analyses on COVID-19 Main Protease - Inhibitor N3 Complex (PDB ID: 6LU7).
32551639 2020. Discovery of New Hydroxyethylamine Analogs against 3CL(pro) Protein Target of SARS-CoV-2: Molecular Docking, Molecular Dynamics Simulation, and Structure-Activity Relationship Studies.



32551855 2020. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.


32592703 2020. Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia.
32579985 2020. Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients: Etoposide for severe COVID-19 patients.


32515499 2020. Higher levels of IL-6 early after tocilizumab distinguish survivors from non-survivors in COVID-19 pneumonia: a possible indication for deeper targeting IL-6.



32519764 2020. Could melatonin be used in COVID-19 patients with laryngopharyngeal reflux disease?


32454982 2020. Amid COVID-19: the importance of developing an positive adverse drug reaction (ADR) and medical device incident (MDI) reporting culture for Global Health and public safety.
32542782 2020. SARS-CoV-2 Viral Inactivation Using Low Dose Povidone-Iodine Oral Rinse-Immediate Application for the Prosthodontic Practice.
32582350 2020. Herbs that might be effective for the management of COVID-19: A bioinformatics analysis on anti-tyrosine kinase property.
32600410 2020. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection.



32539990 2020. A minimal common outcome measure set for COVID-19 clinical research.
32402512 2020. A Case of Coronavirus Disease 2019 Treated With Ciclesonide.
32577056 2020. The Nrf2 Activator (DMF) and Covid-19: Is there a Possible Role?
32537610 2020. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19.



32540604 2020. Iodine, a preventive and curative agent in the COVID-19 pandemic?


32554324 2020. Noradrenergic and serotonergic drugs may have opposing effects on COVID-19 cytokine storm and associated psychological effects.
32540603 2020. Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19.
32563970 2020. Deceiving SARS-CoV-2 molecular-tropism clues - A combinational contemporary strategy.


32554149 2020. Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy.




32405836 2020. Wie ernahre ich mich am besten in Zeiten der Corona-Pandemie? : COVID-19 und Ernahrungsmedizin.


32545268 2020. Potential of Flavonoid-Inspired Phytomedicines against COVID-19.



32550240 2020. Azithromycin Should Not Be Used to Treat COVID-19.
32582329 2020. How Nutrition can help to fight against COVID-19 Pandemic.
32582320 2020. Beyond transmission: Dire need for integration of nutrition interventions in COVID-19 pandemic-response strategies in Developing Countries like Pakistan.
32582873 2020. Evaluation of Ultraviolet-C Light for Rapid Decontamination of Airport Security Bins in the Era of SARS-CoV-2.




32540682 2020. Psychotropics drugs with cationic amphiphilic properties may afford some protection against SARS-CoV-2: A mechanistic hypothesis.



32583654 2020. Baricitinib en el tratamiento de infeccion por SARS-CoV-2.


32548259 2020. Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.
32601278 2020. Numerical evaluation of spray position for improved nasal drug delivery.
32581288 2020. Far-UVC light (222 nm) efficiently and safely inactivates airborne human coronaviruses.
32576928 2020. DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.
32577236 2020. Preventing SARS-CoV-2 infection by blocking a tissue serine protease.
32539647 2020. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients.
32583289 2020. Statistical Evaluation of Clinical Trials Under COVID-19 Pandemic.
32557317 2020. New FDA Guidance on General Clinical Trial Conduct in the Era of COVID-19.


32563584 2020. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report.


32580895 2020. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.


32551456 2020. Use of Spironolactone in SARS-CoV-2 ARDS Patients.


32595360 2020. Interaction of certain monoterpenoid hydrocarbons with the receptor binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties.
32595359 2020. Potentials of plant-based substance to inhabit and probable cure for the COVID-19.



32595355 2020. Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target.


32575350 2020. Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients.




32565126 2020. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.


32573126 2020. Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?

Von „http://coviki.org/cov/index.php?title=Candidate_Compounds_Covid19&oldid=3389“
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis